CU20210070A7 - CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM - Google Patents

CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM

Info

Publication number
CU20210070A7
CU20210070A7 CU2021000070A CU20210070A CU20210070A7 CU 20210070 A7 CU20210070 A7 CU 20210070A7 CU 2021000070 A CU2021000070 A CU 2021000070A CU 20210070 A CU20210070 A CU 20210070A CU 20210070 A7 CU20210070 A7 CU 20210070A7
Authority
CU
Cuba
Prior art keywords
coronavirus
control
compositions including
chimeric antigens
protein
Prior art date
Application number
CU2021000070A
Other languages
Spanish (es)
Inventor
Olivera Ileanet Ávalos
González Yamila Carpio
García Mario Pablo Estrada
González Thailín Lao
Rodríguez Elsa María Rodríguez
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2021000070A priority Critical patent/CU20210070A7/en
Priority to PCT/CU2022/050009 priority patent/WO2023020637A1/en
Publication of CU20210070A7 publication Critical patent/CU20210070A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

<p>Antígenos quiméricos que comprenden un segmento que consiste en el dominio de unión al receptor de la proteína S1 o en la proteína N de dicho virus y el segmento extracelular de la proteína CD154 humana, así como composiciones vacunales contra el coronavirus SARS-CoV2 que comprenden al menos uno de esos antígenos y un adyuvante.</p><p>Chimeric antigens comprising a segment consisting of the receptor-binding domain of the S1 protein or the N protein of said virus and the extracellular segment of the human CD154 protein, as well as vaccine compositions against the SARS-CoV2 coronavirus comprising at least one of those antigens and an adjuvant.</p>

CU2021000070A 2021-08-20 2021-08-20 CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM CU20210070A7 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CU2021000070A CU20210070A7 (en) 2021-08-20 2021-08-20 CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM
PCT/CU2022/050009 WO2023020637A1 (en) 2021-08-20 2022-08-18 Chimeric antigens for the control of coronavirus and compositions containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000070A CU20210070A7 (en) 2021-08-20 2021-08-20 CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM

Publications (1)

Publication Number Publication Date
CU20210070A7 true CU20210070A7 (en) 2023-03-07

Family

ID=83690216

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000070A CU20210070A7 (en) 2021-08-20 2021-08-20 CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM

Country Status (2)

Country Link
CU (1) CU20210070A7 (en)
WO (1) WO2023020637A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951862B1 (en) * 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
CU23544A1 (en) * 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech CHEMICAL VACCINAL ANTIGENS AGAINST THE CLASSICAL SWINE VIRUS VIRUS
JP2023554587A (en) * 2020-11-12 2023-12-28 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Antibodies conjugated or fused to the receptor binding domain of the SARS-COV-2 spike protein and their use for vaccine purposes

Also Published As

Publication number Publication date
WO2023020637A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
CY1122607T1 (en) CHIMERAL ANTIGONE RECEPTORS
CL2021001706A1 (en) Chimeric antigen receptors targeting bcma and methods of using these (divisional application no. 201900326)
BR112019014986A2 (en) antibody targeting bcma and use of it
BR112018009129A2 (en) her2 targeting chimeric antigen receptors
UY37564A (en) ISOLATED FROM LYSINIBACILLUS AND USES OF THE SAME
CL2020001394A1 (en) Combination of a 4-pyrimidinesulfamide derivative with a sglt-2 inhibitor for the treatment of endothelin-related diseases.
BR112017027147A2 (en) hair restoration / growth stimulating agent
CL2016002809A1 (en) Compounds derived from pyrrole, pyridine or piperidine substituted with heterocycles, modulators of the protein-coupled receptor g 40 (gpr40); pharmaceutical composition comprising them; and its use for the treatment of diseases such as diabetes, retinopathy, neuropathy, atherosclerosis, obesity and hypertension.
CO2021010786A2 (en) Inactivated apxia, apxiia, and apxiiia toxins
AR080313A1 (en) COMPOSITIONS OF RECOMBINANT CANINE MACHINE VIRUS (CDV) AND ITS USES
CO2019009787A2 (en) Tryptase Antibodies, Their Compositions, and Their Uses
CO6361948A2 (en) USE OF MYCOPLASMA BOVIS ANTIGEN
CR20110497A (en) NEW ANTI-ALFA5BETA1 ANTIBODIES AND THEIR USES
CL2007000526A1 (en) Chimeric vaccine antigen against avian influenza virus, ia, which contains the extracellular segment of the hemagglutinin of the ia virus envelope and the extracellular segment of the cd154 protein; and composition that understands it.
CL2021003266A1 (en) Natriuretic Peptide Receptor 1 Antibodies and Methods of Use
UY38144A (en) INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE
CO2022002898A2 (en) Compositions comprising tigolaner for the control of parasites
BR112017019792A2 (en) topical ophthalmic formulation and use thereof.
CO2019013786A2 (en) Methods and compositions to reduce the immunogenicity of chimeric notch receptors
BR112018069100A2 (en) a combined vaccine against pcv2 virus infection and mycoplasma hyopneumoniae
BR112015032388A2 (en) methods and compositions for dengue virus vaccines
CL2022000132A1 (en) Skin care compositions
AR106981A1 (en) AN ANTIMICROBIAL COMPOSITION
CU20210070A7 (en) CHIMERIC ANTIGENS FOR THE CONTROL OF CORONAVIRUS AND COMPOSITIONS INCLUDING THEM
CL2007000529A1 (en) Chimeric vaccine antigen against classical swine fever virus, vppc, which contains the extracellular segment of the e2 glycoprotein of the vppc viral envelope and a cd154 immune system stimulating protein; composition that understands it.